Feng, Ningping

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine

Cancer, Hypoxia, and MetabolismMitochondrial Function and Pathology

Cited by 928

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 308

KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells

Mahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Moreno Diaz, B. A., et al. (2023) · Cancer Cell

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 258

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Wang, Z., Sun, K., Xiao, Y., Feng, B., Mikule, K., Ma, X., Feng, N., Vellano, C. P., Federico, L., Marszalek, J. R., et al. (2019) · Scientific Reports

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 253

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

Zhang, L., Yao, Y., Zhang, S., Liu, Y., Guo, H., Ahmed, M., Bell, T., Zhang, H., Han, G., Lorence, E., et al. (2019) · Science Translational Medicine

Cancer, Hypoxia, and MetabolismLymphoma Diagnosis and Treatment

Cited by 233

Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer

Yao, W., Rose, J. L., Wang, W., Seth, S., Jiang, H., Taguchi, A., Liu, J., Yan, L., Kapoor, A., Hou, P., et al. (2019) · Nature

Pancreatic and Hepatic Oncology ResearchProteoglycans and glycosaminoglycans research

Cited by 214

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 123

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Thatikonda, V., Lyu, H., Jurado, S., Kostyrko, K., Bristow, C. A., Albrecht, C., Alpar, D., Arnhof, H., Bergner, O., Bosch, K., et al. (2024) · Nature Cancer

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 76

Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition

Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2021) · Cancer Research

Pancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism

Cited by 48

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Han, L., Cavazos, A., Baran, N., Zhang, Q., Kuruvilla, V. M., Gay, J. P., Feng, N., Battula, V. L., Kantarjian, H. M., Daver, N. G., et al. (2019) · Blood

Acute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism

Cited by 19